Butterfly Network, Inc. (BFLY) stock analysis
Healthcare · Medical Devices
From the 10-K filed 2026-02-27
Business type: Asset play
How it makes money
Butterfly earns revenue by selling handheld semiconductor-based ultrasound devices and recurring cloud software subscriptions to healthcare providers and systems.
Butterfly generates revenue primarily through two main channels: selling physical hardware products such as medical devices and accessories, and providing software and related services. Hardware products include handheld point-of-care ultrasound probes powered by the proprietary Ultrasound-on-Chip technology, which are sold directly or through distributors and eCommerce channels. Software revenue is largely driven by software-as-a-service subscriptions, product support, and partnership support services.
The variable that most directly moves profit is the software and other services mix, which represents the percentage of total revenue coming from recurring software subscriptions and services. This mix increased to 35.0% for the year ended December 31, 2025, driven in part by higher subscription revenue from Butterfly Embedded partnerships. Total revenue reached $97.6 million in 2025 compared to $82.1 million in 2024, while net losses stood at $77.1 million and $72.5 million over the same periods.
What protects it: the moat
Butterfly protects its earnings through a robust portfolio of intellectual property surrounding its proprietary Ultrasound-on-Chip technology.
Management relies heavily on maintaining, protecting, and expanding its portfolio of intellectual property rights, including patents, trade secrets, and know-how, to keep competitors from taking its earnings. The company asserts that its Ultrasound-on-Chip platform is fundamentally different from traditional cart-based hospital ultrasound machines that rely on piezoelectric crystals, allowing it to offer whole-body imaging in a single handheld probe.
However, the filing indicates that success and protection from market competition ultimately depend on continuous market acceptance, obtaining regulatory clearances, and successfully launching current and future products against competing technological developments. Without these ongoing efforts, management's claimed technological advantages may not suffice to deter well-funded medical device competitors.
What growth costs
Butterfly incurs ongoing costs to commercialize products, expand its software offerings, and fund operations through significant net losses.
The company devotes substantial financial resources to develop its products and related services, scale its direct sales force, and establish distribution relationships. To support growth, Butterfly invests in building out its commercial footprint, growing adoption at large-scale healthcare systems, and expanding healthcare system software offerings.
The filing does not disclose specific segregated figures for ongoing maintenance capital expenditures versus growth investments. However, the company continues to absorb substantial operating losses, reporting net losses of $77.1 million and $72.5 million for the years ended December 31, 2025 and 2024 respectively, alongside an accumulated deficit of $879.2 million as of December 31, 2025.
What could damage it
A customer concentration risk could permanently impair earnings if the single customer significantly reduces its purchasing volume.
Butterfly relies on a relatively concentrated customer base for a notable portion of its revenue generation. Specifically, approximately 11% of total revenue in 2025 was generated by sales to a single customer. If this key customer terminates its relationship, reduces its purchasing volume, or shifts to a competing ultrasound platform, Butterfly would experience an immediate and substantial drop in top-line revenue. Because the company already incurs significant operating losses and depends on accelerating commercialization to achieve profitability, such a loss of revenue could severely impair financial stability and force a curtailment of operations.
About Butterfly Network, Inc.
Butterfly Network, Inc. develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally. The company offers Butterfly iQ+ and iQ3 ultrasound devices that can perform whole-body imaging on a single handheld probe integrated with the clinical workflow, and accessible on a user's smartphone, tablet, and almost any hospital computer system; Butterfly Move, merging the mobility of a handheld with the stability of a full cart system; and iQ+ Bladder, a specialty product for bladder scanning market. It also provides Compass AI which offers one system to connect every device, workflow, and department; ScanLab, an AI-powered educational platform that provides written walkthroughs and reference imagery to guide real-time educational scanning; and Butterfly iQ+/iQ3 Vet, a third generation handheld ultrasound system. It sells and markets its products through a direct sales force, distributors, and e-commerce channels. Butterfly Network, Inc. was founded in 2011 and is headquartered in Burlington, Massachusetts.